the aid library

LIST OPTIONS

Filter

8703

Sort by:

Direction:

Download (584)

View PDF (867)

National Health Strategie Plan for Tuberculosis Control in the Kingdom of Cambodia 2011-2015

National Center for Tuberculosis and Leprosy Control (CENAT), Cambodia (2011) CC

Download (580)

View PDF (925)

National Health Strategie Plan for Tuberculosis Control in the Kingdom of Cambodia

National Center for Tuberc ulosis and Leprosy Control (CENAT) , Cambodia (2011) C1

Download (271)

View PDF (365)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (153)

View PDF (174)

Eau, hygiène et assainissement, prévention et contrôle des infections dans les structures de traitement du choléra

UN Children's Fund UNICEF Groupe spécial mondial de lutte contre le Choléra (2019) C_UNICEF

Note technique. Les centres de traitement de choléra fournissent des soins hospitaliers aux patients atteints de choléra pendant les épidémies. Une prise en charge de qualité et l’isolement des patients atteints du choléra sont essentiels pour prévenir les décès et aider à lutter con... more

Download (637)

View PDF (1371)

Guidelines for surveillance of drug resistance in tuberculosis

World Health Organization (2021) C_WHO

6th edition

Download (135)

View PDF (109)

Manual de prevención y control de bacterias multirresintentes

Adriana Jiménez Rojas; Maria Virginias Villegas Asociación Colombiana de Infectiologiá ACIN (2019) C1

Las Infecciones Asociadas a la Atención en Salud (IAAS) son reconocidas en la actualidad como un problema de salud pública y existen lineamientos guber- namentales en la mayoría de los países para constituir sistemas de vigilancia y Programas de Prevención y Control de Infecciones para con... more

Download (748)

View PDF (1345)

Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups
recommended

A. Montresor World Health Organisation (WHO) (2017) C_WHO

Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health. The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution... more

Download (302)

View PDF (1057)

India: Mid-Term Appraisal of National AIDS Control Programme Phase IV (NACP IV): Key Findings and Recommendations

Dr. C. V. Dharma Rao; NACO; Ministry of Health and Family Welfare, Government of India (2016) C1

Download (660)

View PDF (913)

Nigeria National AIDS and STIs Control Programme Annual Report 2014

Federal Ministry of Health, Nigeria (2014) C1

Report

Download (485)

View PDF (782)

Operational Guidelines for ART Centers India

National AIDSControl (NACO), Government of India; Ministry of Health and Family Welfare (2012) C1

The resources provide both the older as well as the updated Operational Guidelines for antiretroviral therapy centres, including administrative issues, functions and establishment of centres, reporting and recording tools, measures to improve retention in HIV care, supply chain management of drugs a... more